PPLPHARMA211.99

Piramal Pharma Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersDIVISLABSYNGENEGLANDWOCKPHARMAASTERDMCOHANCELALPATHLABNATCOPHARMMcap ₹28,134 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations8,171.29,151.28,869.19,205.3
Other Income175.4134.8213.3244.3
Total Income8,346.69,286.09,082.49,449.6
Expenses
+ Cost of Materials Consumed1,976.82,055.71,995.92,196.3
+ Purchases of Stock-in-Trade1,175.81,417.31,430.51,507.9
+ Changes in Inventories-198.6-241.4-187.8-307.5
+ Employee Benefit Expense2,029.52,307.52,415.92,473.0
+ Finance Costs448.5421.6340.8342.7
+ Depreciation & Amortisation740.6816.3831.2857.5
+ Other Expenses1,991.42,167.22,293.02,325.4
Total Expenses8,164.08,944.39,119.59,395.4
EBITDA1,196.31,444.8921.61,010.1
EBIT455.7628.590.4152.6
Profit
PBT before Exceptional Items182.6341.7-37.154.2
+ Exceptional Items-62.80.0-196.1-216.9
Pretax Income119.8341.7-233.3-162.7
+ Current Tax185.4310.1162.1193.2
+ Deferred Tax-23.913.4-12.215.9
Tax Expense161.5323.5149.9209.1
+ Share of Associates & JVs59.572.957.258.2
Net Income17.891.1-325.9-313.6
+ Net Income — Continuing Ops-41.718.2-383.1-371.8
+ Other Comprehensive Income56.779.8338.4263.7
Total Comprehensive Income74.5171.012.4-49.9
Net Income to Common91.1-325.9-313.6
Per Share
Basic EPS0.140.69-2.46-2.37
Diluted EPS0.140.68-2.46-2.37
Other Comprehensive Income — detail
+ Other Comprehensive Income79.8338.4263.7
+ Items NOT to be Reclassified to P&L-5.1-8.2-12.5-17.4
+ Tax on Items NOT to be Reclassified-2.1-3.2-4.4
+ Tax on Items NOT to be Reclassified — alt tag-1.3
+ Items to be Reclassified to P&L62.389.9390.8301.7
+ Tax on Items to be Reclassified3.943.125.0
+ Tax on Items to be Reclassified — alt tag1.8
Comprehensive Income — Owners of Parent74.579.8338.4-41.1
Comprehensive Income — Non-controlling Interests0.0171.00.0
Per Share — as-filed variants
Basic EPS — Continuing Operations0.140.69-2.46-2.37
Diluted EPS — Continuing Operations0.140.68-2.46-2.37
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit5,217.25,919.55,630.55,808.5
Gross Margin %63.8564.6963.4963.10
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)182.6341.7-37.154.2
− Exceptional Items (reconciliation)-62.80.0-196.1-216.9
Net Income Adj (tax-effected)42.991.1-129.8-96.7
EPS Adj0.340.69-0.98-0.73
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Paid Up Equity Capital1,323.01,324.41,327.21,327.4
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.